Jazz Pharmaceuticals is a biopharma company focused on neuroscience and oncology medicines. It is best known for sleep disorder therapies such as Xywav and Xyrem for narcolepsy and for Epidiolex, a plant-derived cannabidiol treatment for certain rare epilepsies. The portfolio also includes oncology and supportive-care products aimed at specialists rather than primary-care blockbusters.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 1,045.7 | — | -718.5 | — |
| Q3 2025 | 1,126.1 | — | 251.4 | — |
| Q4 2025 | 1,197.9 | — | 203.4 | — |
| Q1 2026 | 1,068.9 | — | 293.1 | — |
| Q2 2026 | 1,208.3 | 15.6% | 192.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Millicom International Cellular S.A. (TIGO), Neurocrine Biosciences, Inc. (NBIX), Akamai Technologies, Inc. (AKAM), Lincoln Electric Holdings, Inc. (LECO), Host Hotels & Resorts, Inc. (HST), Innio N.V. (INIO)